Wearlinq eWave 6-Lead ECG Monitor

Wearlinq Labs is a San Francisco, California cardiac monitoring company led by co-founder and CEO Konrad Morzkowski. It builds the eWave, a wireless, continuous, FDA-cleared 6-lead ECG wearable for ambulatory arrhythmia monitoring.

The eWave pairs with a patient smartphone app by Bluetooth, sends data to the LiveLinq full-disclosure waveform viewer including Extended Holter, and is backed by the Wearlinq IDTF, which provides round-the-clock coverage by certified cardiographic technicians. Reports reach clinicians in under 48 hours according to a December 2025 funding article, and the device runs more than five days on one charge.

• Six-lead ECG: wireless, continuous 6-lead recording.
• LiveLinq viewer: full-disclosure waveform viewer including Extended Holter.
• Patient app: Bluetooth connection with digital diary and connectivity check.
• Immediate transmission: data sent about every two minutes when connected.
• Daily STAT reports: with 24/7 concierge support.
• Wearlinq IDTF: round-the-clock coverage by certified cardiographic technicians.

Cardiology clinics replacing wired Holter with wireless 6-lead monitoring for patients with syncope or palpitations. Hospitals outsourcing monitoring report review to a remote technician service. Telehealth cardiology programs enrolling patients without in-person device fitting.

Six leads give broader visibility than single-lead patches, per the company page. Daily STAT reports and 24/7 concierge support help clinics respond to significant findings. Data is available about every two minutes while the patient is connected. A wireless design replaces wired monitors for patients.

Ambulatory ECG monitoring is shifting from wired Holter to lightweight wireless patches and wearables with managed diagnostic services. Southeast Asian hospitals face growing arrhythmia cases and limited ECG technician capacity, which supports demand for monitoring combined with remote reading services.

Headquartered in San Francisco, California. Raised a USD 14 million Series A and USD 5 million venture debt in December 2025, after USD 6.7 million the year before. The eWave received FDA 510(k) clearance in 2022 and the company acquired AMI Cardiac Monitoring. Founding year not stated.